ArticleScientific reports2021
Intermittent radiotherapy as alternative treatment for recurrent high grade glioma: a modeling study based on longitudinal tumor measurements.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02313272 (A Phase I Trial of Hypofractionated Stereotactic Irradiation), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment ofAJNR. American journal of neuroradiology · 2024Trial
- Mathematical model of tumor-macrophage dynamics in glioma to advance myeloid-targeted therapies.Computers in biology and medicine · 2025Article
- Mathematical model of tumor-macrophage dynamics in glioma to advance myeloid-targeted therapies.bioRxiv : the preprint server for biology · 2025Article
- Estimating treatment sensitivity in synthetic and in vitro tumors using a random differential equation model.NPJ systems biology and applications · 2025Article
- Mathematical modeling in radiotherapy for cancer: a comprehensive narrative review.Radiation oncology (London, England) · 2025Review
- A sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high-grade glioma.CPT: pharmacometrics & systems pharmacology · 2025Article
- Validating the predictions of mathematical models describing tumor growth and treatment response.ArXiv · 2025Article
- Mathematical modeling for glioblastoma treatment: scenario generation and validation for clinical patient counseling.Frontiers in oncology · 2025Article
- Calibrating tumor growth and invasion parameters with spectral spatial analysis of cancer biopsy tissues.NPJ systems biology and applications · 2024Article
- Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy.Frontiers in oncology · 2024Article
- A review of mechanistic learning in mathematical oncology.Frontiers in immunology · 2024Review
- Overcoming chemotherapy resistance in low-grade gliomas: A computational approach.PLoS computational biology · 2023Article
- Mathematical modelling of the dynamics of image-informed tumor habitats in a murine model of glioma.Scientific reports · 2023Article
- Predictive digital twin for optimizing patient-specific radiotherapy regimens under uncertainty in high-grade gliomas.Frontiers in artificial intelligence · 2023Article
- Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse.iScience · 2022Article
- Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.Advanced drug delivery reviews · 2022Review
- Site-Specific Considerations on Engineered T Cells for Malignant Gliomas.Biomedicines · 2022Review
- Glioblastoma Treatment: State-of-the-Art and Future Perspectives.International journal of molecular sciences · 2022Review
- A Century of Fractionated Radiotherapy: How Mathematical Oncology Can Break the Rules.International journal of molecular sciences · 2022Review
- Comparison of volumetric and 2D-based response methods in the PNOC-001 pediatric low-grade glioma clinical trial.Neuro-oncology advancesArticle
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Recurrent high grade glioma patients face a poor prognosis for which no curative treatment option currently exists. In contrast to prescribing high dose hypofractionated stereotactic radiotherapy (HFSRT, [Formula: see text] Gy [Formula: see text] 5 in daily fractions) with debulking intent, we suggest a personalized treatment strategy to improve tumor control by delivering high dose intermittent radiation treatment (iRT, [Formula: see text] Gy [Formula: see text] 1 every 6 weeks). We performed a simulation analysis to compare HFSRT, iRT and iRT plus boost ([Formula: see text] Gy [Formula: see text] 3 in daily fractions at time of progression) based on a mathematical model of tumor growth, radiation response and patient-specific evolution of resistance to additional treatments (pembrolizumab and bevacizumab). Model parameters were fitted from tumor growth curves of 16 patients enrolled in the phase 1 NCT02313272 trial that combined HFSRT with bevacizumab and pembrolizumab. Then, iRT +/- boost treatments were simulated and compared to HFSRT based on time to tumor regrowth. The modeling results demonstrated that iRT + boost(- boost) treatment was equal or superior to HFSRT in 15(11) out of 16 cases and that patients that remained responsive to pembrolizumab and bevacizumab would benefit most from iRT. Time to progression could be prolonged through the application of additional, intermittently delivered fractions. iRT hence provides a promising treatment option for recurrent high grade glioma patients for prospective clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.